Medical Device Innovation South Africa: Breaking Down Systemic Barriers
Medical device innovation South Africa is hindered by deep structural obstacles that prevent locally developed technologies from reaching patients, despite the country’s considerable technical expertise. South Africa’s medical technology sector remains trapped in a cycle of heavy import dependence and chronic under-utilisation of equipment, according to Sara Grobbelaar. Between 40% and 70% of donated medical equipment in low- and middle-income countries stays unused due to poor contextual fit, inadequate training, and absent maintenance capacity — creating widespread “medical device graveyards.”
The Cost of Non-Functional Equipment
The scale of wasted resources is staggering. The World Health Organisation estimates that 50–80% of medical equipment in under-resourced health systems is out of service at any given time. In South Africa, the public sector — the dominant purchaser — spends billions on imported devices that frequently cannot be maintained. The local sector, valued at R21–29 billion in 2021, imports approximately 90% of its products. This pattern mirrors most LMICs, where up to 95% of equipment is sourced externally and often donor-financed.
Recent doctoral research from Stellenbosch University reveals that resource mobilisation is simultaneously the most critical and weakest function in the innovation system. Funding appears for early-stage ideas but evaporates during the high-risk validation and scale-up phases. This timing mismatch stalls promising technologies precisely when they need clinical validation and iterative engineering. Medical device innovation South Africa is therefore undermined by misaligned funding cycles that fail to support the full device development journey.
Product-Market Mismatch and Regulatory Roadblocks
Public procurement remains slow, risk-averse, and ill-suited for unproven local innovations. As a result, developers are forced to target the private sector first, producing devices optimised for well-resourced facilities rather than the infrastructure, budgets, and workflows of the public health system where most South Africans receive care. Regulatory navigation, despite being a stated government priority, continues to rank among the lowest-performing areas, leaving small innovators without structured guidance through complex certification processes.
Compounding these issues is the instability of innovation teams. The multi-year journey of medical device development clashes with intermittent funding and policy uncertainty, driving talent loss at critical moments. The near-total absence of early Health Technology Assessment (HTA) further ensures that innovators reach procurement without the clinical, economic, and system-level evidence that decision-makers require.
Mapping the Innovation System Failures
These insights are drawn from two PhD studies conducted at Stellenbosch University’s Innovation Systems research programme in the Department of Industrial Engineering. Using an innovation-systems analytical lens, the research mapped the performance of key functions — including resource mobilisation, regulatory navigation, knowledge development, and market formation — through a 90-stakeholder survey and detailed policy analysis. The studies identify four recurring “walls”: misaligned funding cycles, opaque regulatory pathways, disconnection from public-sector clinical and procurement needs, and unstable innovation teams. These barriers are systemic, not technical.
The findings have direct implications for Health Economics and Outcomes Research (HEOR) and market access strategies. Embedding HTA capacity from the concept phase — rather than treating it as a late-stage gatekeeping exercise — would help innovators design target product profiles and evidence plans that meet public payer requirements from the outset. This shift could dramatically improve adoption rates and long-term cost-effectiveness within South Africa’s constrained health budgets.
Structured public-sector entry mechanisms such as conditional procurement, pilot programmes, and dedicated testing environments are urgently needed. These would allow medical device innovation South Africa to generate real-world evidence inside the very systems the technologies are designed to serve, reducing the current detour through private markets and shortening time-to-reimbursement.
Building a Functional Innovation Ecosystem
Sustainable localisation of medical technology demands deliberate investment in infrastructure that connects demand signals, regulatory support, early HTA, and stable talent pipelines. Without these systemic connections, South Africa will continue to bear high opportunity costs — measured in both financial waste and foregone health outcomes. The proposed reforms offer a coherent roadmap to transform institutional fragments into a functional ecosystem capable of delivering appropriate, maintainable, and cost-effective medical technologies where they are needed most.
